Patient

Age (years) Tumor type
and stage
Radiation source Fraction number Total dose (Gy)
1 47 vagina ca. stage; IIB Co-60 THR 25 50
2 51 Op. corpus ca. stage; IC Co-60 THR 25 50
3 49 Op.  cervix ca. stage; IC Co-60 THR 25 50
4 74 Inop. cervix ca. stage; IIB Co-60 THR 25 50
5 74 Op. endo. ca. stage; IIA Co-60 THR 25 50
6 64 Op. endo. ca. stage; IC Linac-18 MV 25 50
7 43 Cervix ca stage; IIB Co-60 THR  25 50
8 56 Op. endo. ca. stage; IIIA Co-60 THR 25 50
9 58 Op. endo. ca. stage; IIB Co-60 THR 25 50
10 35 Op. endo. ca. stage; IIB Co-60 THR 25 50
11 73 Op. endo. ca. stage; IC Co-60 THR 25 50
12 45 recur. over ca. stage; recur Co-60 THR 25 50
13 71 Inop. cervix ca. stage; IIB Co-60 THR 25 50
14 54 Endo. ca. stage; IIB Co-60 ATC 25 50
15 55 Op. endo. ca. stage; IIIA Co-60 THR 25 50
16 69 Op. cervix ca. stage; IB Co-60 THR 25 50
17 43 endo. ca. stage; IB Co-60 ATC 25 50
18 54 Op. endo. ca. stage; IIA Co-60 ATC 25 50
19 82 Op. endo. ca. stage; IC Co-60 THR 25 50
20 49 Op. endo. ca. stage; IC Linac 18-MV 25 50
ca; carcinoma, Op; operated, Inop; inoperated, endo; endometrium, recur; recurrent
Table 1: Patients ages, tumor types and treatment protocols.